Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLVE: Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis
NCT00049764Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2002
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in severe sepsis comparing Drotrecogin alfa (activated) with Placebo (2 arms). Primary endpoint: Composite Time to Complete Organ Failure Resolution at 14 days. Started Nov 2002; status: completed.
02
Drugs
drotrecogin alfa
03
Conditions
severe sepsis
Beyond the preview
Go deeper on NCT00049764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00049764.